Caladrius Biosciences Inc (NASDAQ:CLBS) is developing cell therapy (CT) products that extract, expand and bolster a patient’s own (autologous) immune cells to treat diseases. CLBS03 is a potentially transformative Phase II candidate for recent-onset type I diabetes (TID), and CLBS14 and CLBS12 target ischemic injury conditions.
CLBS03 immune modulation for TID
CLBS03 seeks to reduce or halt disease progression by preserving the patient’s insulin-producing beta pancreas cells (BPC). Immune T regulatory cells (Tregs) normally modulate the activity of effector T-cells, helping to ensure that host cells are not attacked. In autoimmune diseases like TID, deficient Treg activity may permit effector T-cells to attack the body's own cells (eg BPC in TID). CLBS03 modifies the patient’s Tregs before reintroduction, aiming to restore immune tolerance to BPC. If effective, this can reduce the need for lifelong insulin therapy.
To read the entire report Please click on the pdf File Below: